Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Moderate Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $139.80.

MIRM has been the topic of a number of analyst reports. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. TD Cowen upped their target price on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada upped their target price on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Citizens Jmp upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research note on Monday. Finally, Morgan Stanley upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, June 11th.

Insider Activity

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $93.82, for a total transaction of $469,100.00. Following the sale, the chief financial officer directly owned 44,788 shares of the company’s stock, valued at approximately $4,202,010.16. This represents a 10.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer directly owned 194,309 shares in the company, valued at $18,622,574.56. This represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 8.32% of the stock is currently owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. bought a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $30,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $32,000. Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals during the third quarter worth approximately $33,000. Finally, Summit Securities Group LLC acquired a new position in shares of Mirum Pharmaceuticals during the first quarter worth approximately $42,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $102.04 on Thursday. The stock has a market cap of $6.22 billion, a P/E ratio of -7.50 and a beta of 0.50. The company’s 50-day simple moving average is $98.29 and its 200 day simple moving average is $91.88. Mirum Pharmaceuticals has a twelve month low of $47.89 and a twelve month high of $114.99. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business’s revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.30) EPS. As a group, research analysts forecast that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.